Natural Phenomenon or Process
Genentech Announces 93 Layoffs in California Following Closure of Cancer Immunology Research Unit
Genentech, layoffs, California, cancer immunology research unit, biotech, workforce reduction
Grail Lays Off About 350 Employees, Puts Brakes on New Hires
Grail, layoffs, restructuring, biotech, cancer detection, Galleri test, Illumina, workforce reduction, cost-cutting measures
Boundless Bio Implements Strategic Workforce Reduction to Enhance Operational Efficiency
Boundless Bio, workforce reduction, San Diego, operational efficiency, biotech layoffs
Lexicon Pharmaceuticals Reduces Workforce by 50% to Focus on Diabetes Drug
Lexicon Pharmaceuticals, workforce reduction, diabetes drug, restructuring, Zynquista
AN2 Therapeutics Cuts 50% of Staff and Discontinues Epetraborole Program for MAC Lung Disease
AN2 Therapeutics, epetraborole, MAC lung disease, Phase II/III trial, workforce reduction, restructuring, melioidosis, Chagas disease
Novartis’ Fabhalta Clinches Another FDA Win, This Time in IgA Nephropathy
Novartis, Fabhalta, FDA approval, IgA nephropathy, proteinuria reduction, complement inhibitor, kidney disease
Apellis and Sobi Achieve Significant Breakthrough in Phase 3 Trial for Rare Kidney Disease Treatment
Apellis Pharmaceuticals, Sobi, pegcetacoplan, Phase 3 VALIANT study, C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, proteinuria reduction, kidney disease treatment, FDA approval, European Medicines Agency
BioMarin Restricts Roctavian Sales to U.S., Germany, and Italy Amid Stagnant Sales
BioMarin, Roctavian, hemophilia A gene therapy, U.S., Germany, Italy, sales strategy, profitability, cost reduction
Vir Biotechnology Acquires T-Cell Engagers from Sanofi, Reduces Staff by 25% in Strategic Pipeline Shift
Vir Biotechnology, Sanofi, T-cell engagers, pipeline switch-up, staff reduction, biotech industry, pharmaceuticals
Biopharma Companies uniQure and Arbutus Announce Workforce Reductions to Focus on Priority Programs
uniQure, Arbutus Biopharma, layoffs, workforce reduction, biopharma, priority programs, gene therapy, clinical trials